Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies

Coronavirus disease 2019 (COVID-19) caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as a severe pandemic and caused enormous global health and economical damage. Since December 2019, more than 197 million cases have been reported, causing 4.2 milli...

Full description

Bibliographic Details
Published in:	Computational and Structural Biotechnology Journal
Main Authors:	Daria Beshnova, Yan Fang, Mingjian Du, Yehui Sun, Fenghe Du, Jianfeng Ye, Zhijian James Chen, Bo Li
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Subjects:	SARS-CoV-2 antibodies Binding prediction Regdanvimab antibody Modifications of Regdanvimab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2001037022001556

Similar Items

Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
by: Haein Kim, et al.
Published: (2023-05-01)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
by: Daria S. Fomina, et al.
Published: (2023-10-01)

Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study
by: Soyoon Hwang, et al.
Published: (2024-04-01)

Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit
by: Ulyana A. Markina, et al.
Published: (2022-06-01)

Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
by: Young Rock Jang, et al.
Published: (2023-05-01)

The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
by: Ganghee Chae, et al.
Published: (2022-03-01)

Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis
by: Youn Kyung Kee, et al.
Published: (2024-01-01)

Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain
by: Ping-Han Huang, et al.
Published: (2021-03-01)

Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2
by: Wael Bahnan, et al.
Published: (2022-01-01)

Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
by: Romain Rouet, et al.
Published: (2021-01-01)

Evaluation of Binding and Neutralizing Antibodies for Inactivated SARS-CoV-2 Vaccine Immunization
by: Heng Zhao, et al.
Published: (2024-03-01)

A systematic study on the binding affinity of SARS-CoV-2 spike protein to antibodies
by: Ke An, et al.
Published: (2022-12-01)

Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test
by: Yoonjoo Kim, et al.
Published: (2021-08-01)

Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant
by: Chloé Dimeglio, et al.
Published: (2022-08-01)

Neutralizing Antibody Spectrum in COVID-19 Patients who Became Ill During the Circulation of Different SARS-CoV-2 Variants
by: S. K. Pylaeva, et al.
Published: (2024-11-01)

Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection
by: Song Mu, et al.
Published: (2022-10-01)

Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents
by: Zheng Wang, et al.
Published: (2023-05-01)

Broadly Sarbecovirus-Neutralizing Antibodies Induced by Ancestral SARS-CoV-2 Infection
by: Yiwei Zhang, et al.
Published: (2025-09-01)

Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
by: Xingsu Gao, et al.
Published: (2022-11-01)

Detection of SARS-CoV-2 Nucleocapsid, Spike, and Neutralizing Antibodies in Vaccinated Japanese
by: Rie Midorikawa, et al.
Published: (2022-05-01)

Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants
by: Bo-Seong Jeong, et al.
Published: (2022-12-01)

Performance Evaluation of Three Antibody Binding Assays, a Neutralizing Antibody Assay, and an Interferon-Gamma Release Assay for SARS-CoV-2 According to Vaccine Type in Vaccinated Group
by: Minjeong Nam, et al.
Published: (2023-12-01)

Fever temperatures modulate intraprotein dynamics and enhance the binding affinity between monoclonal antibodies and the spike protein from SARS-CoV-2
by: Dong Gun Kim, et al.
Published: (2022-01-01)

A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein
by: Rong-Hong Hua, et al.
Published: (2023-08-01)

Neutralising and Non-neutralising Antibodies to SARS-CoV-2: Role during Infection and in the Evolution of Antigenic structure
by: S. K. Pylaeva, et al.
Published: (2025-01-01)

Hyperimmunized Chickens Produce Neutralizing Antibodies against SARS-CoV-2
by: Emily J. Aston, et al.
Published: (2022-07-01)

Anti-SARS-CoV-2 spike receptor binding domain (S-RBD) IgG antibodies following CoronaVac administration: a longitudinal study. Anti-SARS-CoV-2 S-RBD IgG antibodies
by: Ph. Liana, et al.
Published: (2023-02-01)

Neutralizing Antibodies against SARS-CoV2
by: Prachi Athavale, et al.
Published: (2023-06-01)

SARS-CoV-2 spike S2-specific neutralizing antibodies
by: Chia-Jung Li, et al.
Published: (2023-12-01)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
by: Gabriele Anichini, et al.
Published: (2021-05-01)

Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
by: Hiroshi Furukawa, et al.
Published: (2022-08-01)

Identification of conserved linear epitopes in the SARS-CoV-2 receptor-binding region using monoclonal antibodies
by: Yujie Yang, et al.
Published: (2023-06-01)

Development and Concordance of Binding and Neutralizing Assays to Determine SARS-CoV-2 Antibody Activity in Human Milk
by: Mallory C. Shriver, et al.
Published: (2025-05-01)

Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening
by: Matthias Hillenbrand, et al.
Published: (2024-02-01)

Serum neutralizing antibody following the vaccination of inactivated SARS-CoV-2 vaccines
by: FU Chunyan, et al.
Published: (2023-09-01)

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study [version 2; peer review: 2 approved]
by: Mansoor Saleh, et al.
Published: (2024-12-01)

Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS‐CoV‐2 neutralization
by: Veronica A. deLima, et al.
Published: (2024-07-01)

Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations
by: Caiqin Hu, et al.
Published: (2022-01-01)

Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19
by: E. A. Kolosova, et al.
Published: (2022-04-01)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01)